<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419077</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0992</org_study_id>
    <nct_id>NCT04419077</nct_id>
  </id_info>
  <brief_title>Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act</brief_title>
  <acronym>REV</acronym>
  <official_title>Interest of Virtual Reality to Prevent Cancer Patient Anxiety Before Chemotherapy or an Invasive Act</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the REV clinical trial is to evaluate the impact of a virtual reality exposure to&#xD;
      decrease patient anxiety before chemotherapy or an invasive act. If positive, the access to&#xD;
      virtual reality exposure is aimed to be used as standard of care at Lyon's hospital to&#xD;
      improve cancer patient well-being in a drug-free manner.&#xD;
&#xD;
      The majority of cancer patients lives with high level of anxiety as soon as diagnosed. This&#xD;
      level anxiety is particularly high before invasive acts but also before chemotherapy by side&#xD;
      effects anticipation.&#xD;
&#xD;
      Hypnosis is a highly interesting drug-free approach to decrease patient's anxiety. It however&#xD;
      requires on site specialists to be available whenever needed.&#xD;
&#xD;
      Virtual reality provides a distractive environment enabled to shift patient focus. It can&#xD;
      support a switch of patient mindset by providing positive emotions.&#xD;
&#xD;
      Since 5 years, this disruptive technology is being more and more used as medical support&#xD;
      thanks to a new generation of headsets enabling improved performance at cheaper prices.&#xD;
&#xD;
      Many publications have now demonstrated the positive impact of virtual reality to take in&#xD;
      charge patients' pain or pre-operational anxiety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the REV study is to demonstrate the difference of anxiety before and&#xD;
      after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y) before&#xD;
      patients undergo an oncological procedure (invasive act or chemotherapy (C1D1).&#xD;
&#xD;
      The investigator's REV study aims to recruit 66 patients among three cohorts (22 patients per&#xD;
      cohort) in 12 months.&#xD;
&#xD;
        -  Breast cancer cohort (patient receiving an adjuvant or neoadjuvant chemotherapy with&#xD;
           doxorubicin and cyclophosphamide)&#xD;
&#xD;
        -  Head or neck cancer cohort (patient treated by concomitant radiochemotherapy)&#xD;
&#xD;
        -  Cancer patient for which an invasive act inducing anxiety is planned (lumbar puncture,&#xD;
           ascites puncture, thoracocentesis, myelogram, bone marrow biopsy, urinary&#xD;
           catheterization, ..)&#xD;
&#xD;
      The REV study aims to impact Lyon's hospital patients' quality of life and well-being by&#xD;
      decreasing their anxiety level during oncological treatments thanks to innovative supportive&#xD;
      cares.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2020</start_date>
  <completion_date type="Anticipated">December 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>44 patients for the cohort &quot; chemotherapy &quot; and 22 patients for the cohort &quot; invasive act &quot;.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of anxiety using the State-Trait Anxiety Inventory before oncologic procedure</measure>
    <time_frame>Before an invasive act or a chemotherapy</time_frame>
    <description>Difference of anxiety before and after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y; A-State Scale) before patients undergo an oncologic procedure (invasive act or chemotherapy (C1D1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of anxiety using a self-evaluation anxiety inventory before oncologic procedure</measure>
    <time_frame>Before an invasive act or a chemotherapy</time_frame>
    <description>Difference of anxiety before and after a virtual reality exposure using a self-evaluation anxiety inventory before patients undergo an oncologic procedure (invasive act or chemotherapy (C1D1).&#xD;
Comparison of responses between self-evaluation anxiety inventory before and after virtual reality exposure just before an oncologic procedure (invasive act or a chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of anxiety using the State-Trait Anxiety Inventory before chemotherapy</measure>
    <time_frame>Just before chemotherapy</time_frame>
    <description>Difference of anxiety before and after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y; A-State Scale) or the Self-evaluation anxiety inventory before patients undergo chemotherapy (C1D1, C2D1, C3D1).&#xD;
Comparison of responses between the STAI-Y; A-State Scale or the Self-evaluation anxiety inventory before and after virtual reality exposure just before chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of anxiety using the State-Trait Anxiety Inventory before invasive act</measure>
    <time_frame>Just before an invasive act</time_frame>
    <description>Difference of anxiety before and after a virtual reality exposure using the State-Trait Anxiety Inventory (STAI-Y; A-State Scale) or the Self-evaluation anxiety inventory before patients undergo an invasive act.&#xD;
Comparison of responses between the STAI-Y; A-State Scale or the Self-evaluation anxiety inventory before and after virtual reality exposure just before an invasive act</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient basal anxiety level just before an oncologic procedure</measure>
    <time_frame>Just before an oncologic procedure</time_frame>
    <description>Patient basal anxiety level using STAI-Y; A-State Scale, STAI-Y; Trait-State Scale or the Self-evaluation anxiety inventory just before an oncologic procedure (invasive act or a chemotherapy).&#xD;
Quotation of patient basal anxiety level using STAI-Y; A-State Scale, STAI-Y; Trait-State Scale or the Self-evaluation anxiety inventory just before an oncological procedure (invasive act or a chemotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of patient anxiety level evolution through 3 cycles of chemotherapy</measure>
    <time_frame>just before virtual reality exposure, after virtual reality exposure, after 1 hour of chemotherapy</time_frame>
    <description>Determination of patient anxiety level evolution through 3 cycles of chemotherapy using the STAI-Y; A-State Scale and the Self-evaluation anxiety inventory (just before virtual reality exposure, after virtual reality exposure, after 1 hour of chemotherapy).&#xD;
Comparison of responses between the STAI-Y; A-State Scale and the Self-evaluation anxiety inventory before virtual reality exposure, after virtual reality exposure and after 1 hour of chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Anxiety</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Breast Cancer</condition>
  <condition>Head Cancer Neck</condition>
  <arm_group>
    <arm_group_label>Virtual reality exposure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Virtual reality exposure just before an oncological procedure (invasive act or a chemotherapy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Virtual reality exposure</intervention_name>
    <description>Patients will be exposed to a 10-20 min virtual reality session just before an oncological procedure (invasive act or chemotherapy).&#xD;
Patients will be able to choose between 4 virtual universes (beach, underwater, forest, space) and seven musical content.</description>
    <arm_group_label>Virtual reality exposure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all patients:&#xD;
&#xD;
          -  Patient Study Information and written informed consent&#xD;
&#xD;
          -  Social Security Affiliation&#xD;
&#xD;
        For breast cancer cohort :&#xD;
&#xD;
          -  Adult patient (&gt;18 years)&#xD;
&#xD;
          -  Histological or cytological proven breast cancer&#xD;
&#xD;
          -  Eligible to an adjuvant or neo-adjuvant IV chemotherapy given every 2 to 3 weeks (with&#xD;
             protocol doxorubicin- cyclophosphamide, docetaxel-cyclophosmadide,&#xD;
             docetaxel-cyclophosphamide-trastuzumab, docetaxel, carboplatine, trastuzumab,&#xD;
             epirubicin-cyclophosphamide, etc)&#xD;
&#xD;
          -  Therapeutic strategy validated in multidisciplinary meeting&#xD;
&#xD;
          -  First chemotherapy cure (C1D1) not initiated yet&#xD;
&#xD;
          -  Patients with a complete healing after resection (for adjuvant chemotherapy)&#xD;
&#xD;
          -  Patients that do not report residual pain with an intensity &gt; 4.&#xD;
&#xD;
        For head, neck and bladder cancer cohort :&#xD;
&#xD;
          -  Adult patient (&gt;18 years)&#xD;
&#xD;
          -  Histological or cytological proven head, neck or bladder cancer&#xD;
&#xD;
          -  Patient eligible for an adjuvant or neoadjuvant based on cisplatin.&#xD;
&#xD;
          -  Therapeutic strategy validated in multidisciplinary meeting&#xD;
&#xD;
          -  First chemotherapy cure (C1D1) not initiated yet&#xD;
&#xD;
          -  Patients with a complete healing after resection.&#xD;
&#xD;
          -  Patients that do not report residual pain with an intensity &gt; 4.&#xD;
&#xD;
        For invasive act leading to potential anxiety cohort :&#xD;
&#xD;
          -  Adult patient (&gt;18 years)&#xD;
&#xD;
          -  Histological or cytological proven cancer&#xD;
&#xD;
          -  Patient with a planned hospitalization at oncological unit&#xD;
&#xD;
          -  Eupneic patient&#xD;
&#xD;
          -  Afebrile patient&#xD;
&#xD;
        Patient for whom an invasive act leading to potential anxiety is planned (excluding&#xD;
        percutaneous implantable chamber) :&#xD;
&#xD;
          -  Puncture&#xD;
&#xD;
          -  Deep biopsy&#xD;
&#xD;
          -  Sounding&#xD;
&#xD;
          -  Endoscopy without general anesthesia&#xD;
&#xD;
          -  myelogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a consciousness disturbance or a spatio-temporal disturbance&#xD;
&#xD;
          -  Claustrophobic patient&#xD;
&#xD;
          -  Patient with a non-stabilized psychiatric pathology&#xD;
&#xD;
          -  Patient with seizure crisis background&#xD;
&#xD;
          -  Patient with a visual or hearing disturbance that is not compatible with video&#xD;
             watching and sound listening&#xD;
&#xD;
          -  Patients with out-of range clinical parameters (arterial pressure, cardiac&#xD;
             frequency,..)&#xD;
&#xD;
          -  Patients with out-of range blood parameters that are not compatible with chemotherapy&#xD;
             or an invasive act.&#xD;
&#xD;
          -  Patient with a life expectancy below 3 months.&#xD;
&#xD;
          -  Impossibility to track and follow patient (any reason)&#xD;
&#xD;
          -  Patient deprived of liberty or subjected to guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie HAMAILI</last_name>
    <phone>4 78 86 43 21</phone>
    <phone_ext>+33</phone_ext>
    <email>marie.hamaili@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien PERON, MD</last_name>
    <phone>4 78 86 43 18</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.peron@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'oncologie médicale, Institut de Cancérologie des Hospices Civils de Lyon, Hôpital Lyon sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie HAMAILI</last_name>
      <phone>4 78 86 43 21</phone>
      <phone_ext>+33</phone_ext>
      <email>marie.hamaili@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien PERON, MD</last_name>
      <phone>4 78 86 43 18</phone>
      <phone_ext>+33</phone_ext>
      <email>julien.peron@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marie HAMAILI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

